Sec. 1004. DRUG SHORTAGE LIST
396 words·~2 min read·
/statute-compilations/comps-9932/sec-1004A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
## SEC. 1004 DRUG SHORTAGE LIST Chapter V (21 U.S.C. 351 et seq.) is amended by inserting after section 506D, as added by section 1003 of this Act, the following: > > ## “SEC. 506E DRUG SHORTAGE LIST > > **[**[21 U.S.C. 356e](/us/usc/t21/s356e)**]** > > > ### “(a) Establishment > > The Secretary shall maintain an up-to-date list of drugs that are determined by the Secretary to be in shortage in the United States. > > > ### “(b) Contents > > For each drug on such list, the Secretary shall include the following information: > > > #### “(1) > > The name of the drug in shortage, including the National Drug Code number for such drug. > > > #### “(2) > > The name of each manufacturer of such drug. > > > #### “(3) > > The reason for the shortage, as determined by the Secretary, selecting from the following categories: > > > ##### “(A) > > Requirements related to complying with good manufacturing practices. > > > ##### “(B) > > Regulatory delay. > > > ##### “(C) > > Shortage of an active ingredient. > > > ##### “(D) > > Shortage of an inactive ingredient component. > > > ##### “(E) > > Discontinuation of the manufacture of the drug. > > > ##### “(F) > > Delay in shipping of the drug. > > > ##### “(G) > > Demand increase for the drug. > > > #### “(4) > > The estimated duration of the shortage as determined by the Secretary. > > > ### “(c) Public Availability > > > #### “(1) In general > > Subject to paragraphs
(2)and (3), the Secretary shall make the information in such list publicly available. > > > #### “(2) Trade secrets and confidential information > > Nothing in this section alters or amends section 1905 of title 18, United States Code, or section 552(b)(4) of title 5 of such Code. > > > #### “(3) Public health exception > > The Secretary may choose not to make information collected under this section publicly available under paragraph
(1)or section 506C(c) if the Secretary determines that disclosure of such information would adversely affect the public health (such as by increasing the possibility of hoarding or other disruption of the availability of drug products to patients).” > .
Connectionstraces to 2
Traces to 2 documents
Citation graph
cites case law
Cites 2Cited by 0 across 0 sources